

**EFFECTIVE DATE:** 06/0/2006

**POLICY LAST UPDATED:** 03/04/2014

## OVERVIEW

In radiofrequency ablation (RFA), a probe is inserted into the center of a tumor and the noninsulated electrodes, which are shaped like prongs, are projected into the tumor; heat is generated locally by a high frequency, alternating current that flows from the electrodes. The local heat treats the tissue adjacent to the probe, resulting in a 3- to 5-cm sphere of dead tissue. The cells killed by RFA are not removed but are gradually replaced by fibrosis and scar tissue. If there is local recurrence, it occurs at the edge, and in some cases, may be retreated. RFA may be performed percutaneously, laparoscopically, or as an open procedure.

## PRIOR AUTHORIZATION

Prior authorization is required for BlueCHiP for Medicare and recommended for Commercial Products

## POLICY STATEMENT

Radiofrequency ablation of hepatic tumors is medically necessary when the medical criteria below is met. All other indications are considered not medically necessary due to lack of peer-reviewed literature which support improved health outcomes.

## MEDICAL CRITERIA

Primary hepatocellular carcinoma

Radiofrequency ablation may be considered medically necessary as a primary treatment of HCC for patients when one of the following criteria is met.

- o there are no more than 3 nodules measuring 5 cm's or less, and all tumor foci can be adequately treated
- o as a bridge to transplant, where the intent is to prevent further tumor growth and to maintain a patient's candidacy for liver transplant.
- o not a candidates for curative resections (e.g., due to location of lesion(s) and/or comorbid conditions)

Hepatic metastases from neuroendocrine tumors

Radiofrequency ablation may be considered medically necessary when all the following criteria is met;

- o not a candidates for curative resections (e.g., due to location of lesion(s) and/or comorbid conditions),
- o not a candidates for liver transplantation.

Metastatic colorectal cancer

Radiofrequency ablation of metastatic colorectal cancer may be considered medically necessary when all of the following criteria are met;

- o as a primary treatment of hepatic metastases of 4-5 or fewer hepatic lesions, measuring 5 cm or less in diameter from colorectal cancer in the absence of extrahepatic metastatic disease when all tumor foci can be adequately treated,
- o should not be candidates for curative resections (e.g., due to location of lesion(s) and/or comorbid conditions)

## BACKGROUND

Hepatic tumors can arise either as primary liver cancer (hepatocellular cancer [HCC]) or by metastasis to the liver from other tissues. Local therapy for hepatic metastasis may be indicated when there is no extrahepatic disease, which rarely occurs for patients with primary cancers other than colorectal carcinoma or certain

Hepatic tumors can arise either as primary liver cancer (hepatocellular cancer [HCC]) or by metastasis to the liver from other tissues. Local therapy for hepatic metastasis may be indicated when there is no extrahepatic disease, which rarely occurs for patients with primary cancers other than colorectal carcinoma or certain neuroendocrine malignancies. At present, surgical resection with adequate margins or liver transplantation constitutes the only treatments available with demonstrated curative potential. However, the majority of hepatic tumors are unresectable at diagnosis, due either to their anatomic location, size, number of lesions, or underlying liver reserve.

Neuroendocrine tumors are tumors of cells that possess secretory granules and originate from the neuroectoderm. Neuroendocrine cells have roles both in the endocrine system and the nervous system. They produce and secrete a variety of regulatory hormones, or neuropeptides, which include neurotransmitters and growth factors. Overproduction of the specific neuropeptides produced by the cancerous cells causes a variety of symptoms depending on the hormone produced. They are rare, with an incidence of 2-4 per 100,000 per year. Treatment of liver metastases is undertaken to prolong survival and reduce endocrine-related symptoms, as well as symptoms related to the hepatic mass.

Radiofrequency ablation (RFA) has been investigated as a treatment for unresectable hepatic tumors, both as primary treatment and as a bridge to liver transplant. In the latter setting, it is hoped that RFA will reduce the incidence of tumor progression while awaiting transplantation and thus maintain a patient's candidacy for liver transplant during the wait time for a donor organ. This issue has become less problematic with additional priority now assigned for patients with stage T2 hepatocellular cancer (HCC).

Various locoregional therapies for unresectable liver tumors have been investigated: RFA, cryosurgical ablation (cryosurgery), laser ablation, trans-hepatic artery embolization/chemoembolization (TACE), microwave coagulation, percutaneous ethanol injection, and radioembolization (Yttrium-90 microspheres).

Currently, there is less evidence available for patients treated with RFA to specifically downsize (downstage) tumors (tumors of stage greater than T2) to meet priority transplant criteria, and its use for this application is considered investigational.

The published evidence for demonstrating improved health outcomes with RFA of other hepatic metastatic tumors (e.g., breast cancer and sarcoma) is lacking. Comparative trials are needed for these malignancies that may have associated systemic disease. Use of RFA in these tumors is considered investigational under this policy; the data are insufficient to change this policy statement

#### **COVERAGE**

Benefits may vary between groups/contracts. Please refer to the appropriate Evidence of Coverage or Subscriber Agreement for the applicable surgery benefits and for limitations of benefits/coverage when services are not medically necessary.

#### **CODING**

BlueCHiP for Medicare and Commercial

The following CPT Codes are medically necessary when the medical criteria above is met:

47370  
47380  
47382  
76940

#### **RELATED POLICIES**

None

## PUBLISHED

Provider Update	May 2014
Provider Update	Mar 2012
Provider Update	May 2011
Provider Update	May 2008

## REFERENCES

McWilliams JP, Yamamoto S, Raman SS et al. Percutaneous ablation of hepatocellular carcinoma: current status. *J Vasc Interv Radiol* 2010; 21(8 suppl):S204-13.

Cho YK, Kim JK, Kim MY et al. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. *Hepatology* 2009; 49(2):453-9.

Shen A, Zhang H, Tang C et al. A systematic review of radiofrequency ablation versus percutaneous ethanol injection for small hepatocellular carcinoma up to 3 cm. *J Gastroenterol Hepatol* 2013; 28(5):793-800.

Xu G, Qi FZ, Zhang JH et al. Meta-analysis of surgical resection and radiofrequency ablation for early hepatocellular carcinoma. *World J Surg Oncol* 2012; 10:163.

Tiong L, Maddern GJ. Systematic review and meta-analysis of survival and disease recurrence after radiofrequency ablation for hepatocellular carcinoma. *Br J Surg* 2011; 98(9):1210-24.

Huang YZ, Zhou SC, Zhou H et al. Radiofrequency ablation versus cryosurgery ablation for hepatocellular carcinoma: a meta-analysis. *Hepatogastroenterology* 2013; 60(127).

Feng K, Yan J, Li X et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. *J Hepatol* 2012; 57(4):794-802.

Organ Procurement and Transplant Network. Organ Distribution: Allocation of Livers (3.6.4.4). Available online at: [http://optn.transplant.hrsa.gov/PoliciesandBylaws2/policies/pdfs/policy\\_8.pdf](http://optn.transplant.hrsa.gov/PoliciesandBylaws2/policies/pdfs/policy_8.pdf). Last accessed June 2013.

Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. *N Engl J Med* 1996; 334(11-Jan):693-9.

Fisher RA, Maluf D, Cotterell AH et al. Non-resective ablation therapy for hepatocellular carcinoma: Effectiveness measured by intention to treat and dropout from liver transplant waiting list. *Clin Transplant* 2004; 18(5):502-12. Yamashiki N, Tateishi R, Yoshida H et al.

Ablation therapy in containing extension of hepatocellular carcinoma: a simulative analysis of dropout from the waiting list for liver transplantation. *Liver Transpl* 2005; 11(5):508-14.

Mazzaferro V, Battiston C, Perrone S et al. Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. *Ann Surg* 2004; 240(5):900-9.

Lu DS, Yu NC, Raman SS et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. *Hepatology* 2005; 41(5):1130-7.

Belghiti J, Carr BI, Greig PD et al. Treatment before liver transplantation for HCC. *Ann Surg Oncol* 2008; 15(4):993-1000. 15.

Porrett PM, Peterman H, Rosen M et al. Lack of benefit of pretransplant locoregional hepatic therapy for hepatocellular cancer in the current MELD era. *Liver Transpl* 2006; 12(4):665-73.

Yao FY, Kerlan RK, Jr., Hirose R. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. *Hepatology* 2008; 48(3):819-27.

Pomfret EA, Washburn K, Wald C. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. *Liver Transpl* 2010; 16(3):262-78.

Yao FY, Hirose R, LaBerge JM et al. A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation. *Liver Transpl* 2005; 11(12):1505-14.

Sauer P, Kraus TW, Schemmer P et al. Liver transplantation for hepatocellular carcinoma: is there evidence for expanding the selection criteria? *Transplantation* 2005; 80(1 Suppl):S105-8.

Fernandez JA, Robles R, Marin C et al. Can we expand the indications for liver transplantation among hepatocellular carcinoma patients with increased tumor size? *Transplant Proc* 2003; 35(5):1818-20.

Yao FY, Ferrell L, Bass NM et al. Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. *Liver Transpl* 2002; 8(9):765-74.

Yao FY, Ferrell L, Bass NM et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. *Hepatology* 2001; 33(6):1394-403.

Merli M, Nicolini G, Gentili F et al. Predictive factors of outcome after liver transplantation in patients with cirrhosis and hepatocellular carcinoma. *Transplant Proc* 2005; 37(6):2535-40.

Yao FY, Kinkhabwala M, LaBerge JM et al. The impact of pre-operative loco-regional therapy on outcome after liver transplantation for hepatocellular carcinoma. *Am J Transplant* 2005; 5(4 pt 1):795-804.

Kemeny N. Management of liver metastases from colorectal cancer. *Oncology (Williston Park)* 2006; 20(10):1161-76. 26.

McKay A, Dixon E, Taylor M. Current role of radiofrequency ablation for the treatment of colorectal liver metastases. *Br J Surg* 2006; 93(10):1192-202.

Lencioni R, Crocetti L, Cioni D et al. Percutaneous radiofrequency ablation of hepatic colorectal metastases: technique, indications, results, and new promises. *Invest Radiol* 2004; 39(11):689-97.

Cirocchi R, Trastulli S, Boselli C et al. Radiofrequency ablation in the treatment of liver metastases from colorectal cancer. *Cochrane Database Syst Rev* 2012; 6:CD006317.

Weng M, Zhang Y, Zhou D et al. Radiofrequency ablation versus resection for colorectal cancer liver metastases: a meta-analysis. *PLoS One* 2012; 7(9):e45493.

Pathak S, Jones R, Tand JMF et al. Ablative therapies for colorectal liver metastases: a systematic review. *Colorectal Dis* 2011; 13(9):e252-65.

Guenette JP, Dupuy DE. Radiofrequency ablation of colorectal hepatic metastases. *J Surg Oncol* 2010; 102(8):978-87. 32.

Abdalla EK, Vauthey JN, Ellis LM et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. *Ann Surg* 2004; 239(6):818-27.

Ruers TJ, Joosten JJ, Wiering B et al. Comparison between local ablative therapy and chemotherapy for non-resectable colorectal metastases: a prospective study. *Ann Surg Oncol* 2007; 14(3):1161-9.

Van TAA, Meijerink MR, Sietses C et al. Long-term results of radiofrequency ablation for unresectable colorectal liver metastases: a potentially curative intervention. *Br J Radiol* 2011; 84(1002):556-65.

Berber E, Siperstein A. Local recurrence after laparoscopic radiofrequency ablation of liver tumors: An analysis of 1032 tumors. *Ann Surg Oncol* 2008; 15(10):2757-64

Mazzaglia PJ, Berber E, Milas M et al. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. *Surgery* 2007; 142(1):10-9.

Elias D, Goere D, Leroux G et al. Combined liver surgery and RFA for patients with gastroenteropancreatic endocrine tumors presenting with more than 15 metastases to the liver. *Eur J Surg Oncol* 2009; 35(10):1092-7.

Venkatesan AM, Locklin J, Lai EW et al. Radiofrequency ablation of metastatic pheochromocytoma. *J Vasc Interv Radiol* 2009; 20(11):1483-90.

Meloni MF, Andreano A, Laeseke PF et al. Breast cancer liver metastases: US-guided percutaneous radiofrequency ablation—intermediate and long-term survival rates. *Radiology* 2009; 253(3):861-9.

Jakobs TF, Hoffmann RT, Schrader A et al. CT-guided radiofrequency ablation in patients with hepatic metastases from breast cancer. *Cardiovasc Intervent Radiol* 2009; 32(1):38-46.

Lawes D, Chopada A, Gillams A et al. Radiofrequency ablation (RFA) as a cytoreductive strategy for hepatic metastasis from breast cancer. *Ann R Coll Surg Engl* 2006; 88(7):639-42.

Jones RL, McCall J, Adam A et al. Radiofrequency ablation is a feasible therapeutic option in the multi modality management of sarcoma. *Eur J Surg Oncol* 2010; 36(5):477-82.

Pawlik TM, Vauthey JN, Abdalla EK et al. Results of a single-center experience with resection and ablation for sarcoma metastatic to the liver. *Arch Surg* 2006; 141(6):537-44.

Gervais DA, Goldberg SN, Brown DB et al. Society of Interventional Radiology position statement on percutaneous radiofrequency ablation for the treatment of liver tumors. *J Vasc Interv Radiol* 2009; 3-8. Available online at: [www.sirweb.org/clinical/cpg/PS\\_on\\_Percutaneous\\_RF\\_for\\_the\\_Treatment\\_of\\_Liver\\_Tumors.pdf](http://www.sirweb.org/clinical/cpg/PS_on_Percutaneous_RF_for_the_Treatment_of_Liver_Tumors.pdf). Last accessed June 2013.

National Comprehensive Cancer Network (NCCN). Hepatobiliary Cancers (V.1.2013). Available online at: [http://www.nccn.org/professionals/physician\\_gls/pdf/hepatobiliary.pdf](http://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf). Last accessed June 2013.

National Comprehensive Cancer Network (NCCN). Colon Cancer (V.3.2013). Available online at: [http://www.nccn.org/professionals/physician\\_gls/pdf/colon.pdf](http://www.nccn.org/professionals/physician_gls/pdf/colon.pdf). Last accessed June 2013.

National Comprehensive Cancer Network (NCCN). Neuroendocrine Tumors (V.2.2013). Available online at: [http://www.nccn.org/professionals/physician\\_gls/pdf/neuroendocrine.pdf](http://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf). Last accessed June 2013.

National Institute for Clinical Excellence (NICE). Radiofrequency ablation for colorectal liver metastases-guidance(IPG327). 2009. Available online at: <http://guidance.nice.org.uk/IPG327>. Last accessed June 2013.

National Institute for Clinical Excellence (NICE). Radiofrequency ablation of hepatocellular carcinoma (IPG327). 2003. Available online at: <http://guidance.nice.org.uk/IPG2>. Last accessed June 2013.

**CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS**

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

